Stock A068270 CELLTRION, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Celltrion, Inc.

Equities

A068270

KR7068270008

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
179,500 KRW -0.11% Intraday chart for Celltrion, Inc. +4.97% -10.92%
Apr. 24 Market Share of Celltrion’s Remsima Rises to 74% in Europe MT
Apr. 17 Celltrion, Inc. announces an Equity Buyback for 436,047 shares. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Market Share of Celltrion’s Remsima Rises to 74% in Europe
MT
MDL Panel Grants Transfer Of Aflibercept BPCIA Case
AQ
Celltrion, Inc. announces an Equity Buyback for 436,047 shares.
CI
Celltrion, Inc. authorizes a Buyback Plan.
CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024.
CI
Updates On Aflibercept BPCIA Litigation
AQ
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.
CI
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.
AQ
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US
MT
Celltrion's Autoimmune Disease Treatment Hits US Markets
MT
South Korean Shares Slightly Slip as Investors Seek Cues on Future Rate Direction from US Fed
MT
Celltrion Announces 75 Billion Won Share Buyback Plan
MT
Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab)
AQ
Celltrion, Inc. announces an Equity Buyback for 425,895 shares.
CI
Celltrion, Inc. authorizes a Buyback Plan.
CI
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent
AQ
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings
MT
Celltrion's Net Profit Nosedives 98.5% in Q4 2023 as Revenue Declines 25%
MT
Celltrion Submits An ABLA For Actemra® (Tocilizumab) Proposed Biosimilar CT-P47
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A068270 Stock
  4. News Celltrion, Inc.